Company:  HYPERION THERAPEUTICS INC (HPTX)
Form Type:  10-K
Filing Date:  2/25/2013 
CIK:  0001386858 
Address:  2000 SIERRA POINT PARKWAY
SUITE 400
 
City, State, Zip:  BRISBANE, California 94005 
Telephone:  650-745-7802 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$25.53  
Change: 
-0.08 (-0.31%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$517.34M
Description of Business
We are a commercial biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Our products, RAVICTI� (glycerol phenylbutyrate) Oral liquid, BUPHENYL� and AMMONAPS� (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. Ammonia is produced in the intestine after a person eats protein and is normally detoxified in the liver by conversion to urea. Elevated levels of ammonia are potentially toxic and can lead to severe medical complications which may include death. We have developed RAVICTI, which we launched during the first quarter of 2013, to treat most urea cycle disorders (�UCD�) including 7 of the 8 most prevalent UCD subtypes, and are developing glycerol phenylbutyrate (�GPB�), the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy (�HE�). UCD and HE are diseases in which blood ammonia is elevated.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS
      ITEM 1A. RISK FACTORS
      ITEM 1B. UNRESOLVED STAFF COMMENTS
      ITEM 2. PROPERTIES
      ITEM 3. LEGAL PROCEEDINGS
      ITEM 4. MINE SAFETY DISCLOSURES
    PART II
      ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED ...
      ITEM 6. SELECTED FINANCIAL DATA
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Results of Operations
        Liquidity and Capital Resources
      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
      ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      ITEM 9A. CONTROLS AND PROCEDURES
      ITEM 9B. OTHER INFORMATION
    PART III
      ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
      ITEM 11. EXECUTIVE COMPENSATION
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND ...
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND ...
      ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
    PART IV
      ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
    SIGNATURES
    Report of Independent Registered Public Accounting Firm
    BALANCE SHEET
    INCOME STATEMENT
    STOCKHOLDERS EQUITY
    STOCKHOLDERS EQUITY
    CASH FLOW
    Notes to Consolidated Financial Statements
    EXHIBIT INDEX
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO
BROKERAGE PARTNERS